Part 7 — For families

26. Running a family research program

Parent-led rare disease programs have produced real therapies. The ones that succeed tend to share a recognizable shape.

What effective programs do:

A distinctive advantage a family in this condition may have. As of writing there is no published iPSC-derived neuronal model of STAG2 duplication. That means an early patient-derived line in this condition is likely to be among the first in existence (Module 7) — which makes it a collaboration magnet. Other labs will want access. That is leverage: it can be exchanged for expertise, assays, co-authorship, and data.

The failure modes to guard against:

• Single-hypothesis capture. Betting everything on one compound or one idea. Portfolios survive; single bets usually don't.
• Losing the child in the program. Excellent day-to-day care — speech, OT, education, behavior, seizure management — is not in competition with research. It is the thing that determines your child's actual life over the next decade, while research runs on a longer clock.
• Burnout. This is a multi-year effort. Pace accordingly.
• Isolation. Adjacent communities (MECP2 duplication families, CdLS families) have solved problems you're about to hit. Talk to them.

References:

• Chan Zuckerberg Initiative — Rare As One — a program built specifically to support patient-led research organizations. Study the model even if you don't apply.
• Global Genes — rare disease advocacy resources and community.

27. How to email a scientist

Cold emails from families work far more often than people expect — if they're written well. Researchers in rare disease are usually motivated by exactly your situation. The barrier is their time, not their willingness.

The structure that works — a template to fill in:

Subject: Xq25/STAG2 duplication — parent, patient-derived iPSC line available

Dear Prof. <Name>,

[1 line: who you are]
I'm the parent of an <age>-year-old with an Xq25 duplication
encompassing STAG2.

[1–2 lines: why THEM specifically — prove you read their work]
Your <year> paper on <specific thing> is directly relevant to a
question we're facing about <specific thing>.

[2–3 lines: what you have — lead with your assets]
We have patient-derived iPSCs, now differentiating to neurons, at
<institution>. Clinical baseline documented since <year>. Modest
funding secured.

[1 line: a specific, small ask]
Would you be open to a 20-minute call? I'd value your view on
whether <specific question>.

[1 line: make it easy to decline]
If this isn't your area, a pointer to someone better placed would
be just as helpful.

Thank you,
<Your name>

Rules:

• Under 200 words. Every additional paragraph reduces reply probability.
• Prove you read their work. One specific reference does more than any amount of enthusiasm.
• Lead with assets, not need. A rare patient-derived cell line, clinical data, funding, and total commitment together make a genuinely attractive collaboration proposition — present it as one.
• Make the ask small and concrete. "20-minute call" beats "help us."
• Make declining easy. Reduces the cost of replying, which raises reply rates.
• Follow up once, after ~2 weeks. Then stop.
• Warm introductions beat cold email by a wide margin. Ask your child's clinician, or the lab you already work with, to make them — this costs them little and helps enormously.

28. The questions that separate rigor from sloppiness

A reference list you can bring to any scientific conversation. You do not need to ask all of them — but knowing they exist changes how you listen.

About the model:

• What are you comparing the cells to? (Module 16)
• Is an isogenic corrected line planned?
• Which differentiation protocol, and why that one? (Module 15)
• Has the iPSC line been karyotyped, and the duplication re-confirmed?
• How many independent biological replicates?

About the phenotype — the critical set:

• What measurable difference have you actually found between the patient neurons and controls?
• How reproducible is it across differentiations?
• Does it replicate the published Kumar 2015 signature, including OPHN1? (Module 7)
• What's the effect size — and is the assay window big enough to screen on? (Z-factor)
• What happens to the program if no robust phenotype emerges?

About the screen:

• Which compound library, and how many compounds? (Module 18)
• What's the primary readout, and what's the orthogonal confirmation?
• How are you controlling for compounds that are simply toxic?
• At what stage do you filter for brain penetrance?

About the plan:

• What's the timeline to first screening data?
• What's funded, and what isn't?
• What's the most likely thing to go wrong?
• Will the cell line be shared with other STAG2 groups?
• What would make you abandon this approach? (A scientist who has thought about kill criteria is a scientist thinking clearly.)

How to ask. Curious, not adversarial. "Help me understand…" and "What would you want to know if you were me?" open doors that interrogation closes. You are trying to build a decade-long partnership, not win an exchange. Good scientists genuinely enjoy these questions — they're the questions they ask each other.

29. Funding

The tiers, and what each unlocks:

Where money realistically comes from for a program like this:

1. Family and network — fastest, no strings; typically seeds the first steps.
2. Disease-agnostic rare disease foundations — the cohesinopathy framing (Module 9) helps here.
3. Institutional foundations — the hospital or university foundation attached to wherever the work is being done.
4. Government — NIH/NCATS (US), CIHR/Genome Canada (Canada), and equivalents elsewhere. Slow, large, competitive; usually requires the academic PI to lead.
5. Industry partnership — relevant once there's a target and a model; the PRV incentive (Module 22) is a real argument.

The most efficient use of early money is usually to de-risk the next step so that larger funders will engage. A clean, published cellular model is exactly the kind of asset that makes a bigger grant fundable. Framing donations this way — "this specific $40k produces this specific result, which unlocks this specific grant" — is far more compelling than a general appeal.

Also worth knowing: many labs have unfunded capacity — a student who needs a project, an instrument with idle time. Modest, well-targeted funding is often the difference between an experiment happening this year and not at all.

30. Ethics, consent, data, and IP

Unglamorous, and genuinely consequential. Decisions made casually now constrain options later.

Consent and the child's interests. A child under the age of majority cannot legally consent — a parent or guardian does — but the child's assent matters, and matters more each year. As they grow, involve them at whatever level they can engage with. Their cells, their data, their body, ultimately their decision.

Cell line ownership and sharing. Key questions to settle explicitly, ideally in writing:

• Who owns the iPSC line? (Usually the institution, but the consent terms govern use.)
• Can it be shared with other labs? Under what conditions? You generally want a permissive answer — more labs, more shots on goal.
• Can it be commercialized? What happens if a company wants it?
• Can consent be withdrawn later?

Data sharing. Genomic data is identifying. There is a real trade-off:

• Sharing accelerates science. Registries and databases (DECIPHER, etc.) are how ultra-rare patients find each other and how cohorts form.
• Sharing is hard to undo. Once data is out, it is out.

For most ultra-rare families the calculus favors sharing, because isolation is the bigger threat. But it should be a decision, made deliberately, not a default.

Intellectual property. If a discovery emerges from your child's cells, IP questions arise. Families are sometimes surprised to find they have no stake. This is not primarily about money — it's about control: retaining influence over whether a therapy actually gets developed and reaches patients rather than being shelved. Worth raising early, calmly, and in writing.

Publication and credit. Ask about co-authorship or acknowledgment where the family's contribution is substantive. Beyond fairness, being named on the literature makes you a visible, credible node in the field — which pays off in collaborations.

Key terms:

• Assent — a child's agreement, alongside parental consent.
• Broad consent — permission for unspecified future research.
• MTA (Material Transfer Agreement) — the contract governing sending cells between institutions.
• De-identification — removing identifying information from data.
• IRB / REB — institutional ethics board.